» Articles » PMID: 33374170

GPER1 and MicroRNA: Two Players in Breast Cancer Progression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Dec 30
PMID 33374170
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the main cause of morbidity and mortality in women worldwide. However, the molecular pathogenesis of breast cancer remains poorly defined due to its heterogeneity. Several studies have reported that G Protein-Coupled Estrogen Receptor 1 (GPER1) plays a crucial role in breast cancer progression, by binding to estrogens or synthetic agonists, like G-1, thus modulating genes involved in diverse biological events, such as cell proliferation, migration, apoptosis, and metastasis. In addition, it has been established that the dysregulation of short sequences of non-coding RNA, named microRNAs (miRNAs), is involved in various pathophysiological conditions, including breast cancer. Recent evidence has indicated that estrogens may regulate miRNA expression and therefore modulate the levels of their target genes, not only through the classical estrogen receptors (ERs), but also activating GPER1 signalling, hence suggesting an alternative molecular pathway involved in breast tumor progression. Here, the current knowledge about GPER1 and miRNA action in breast cancer is recapitulated, reporting recent evidence on the liaison of these two players in triggering breast tumorogenic effects. Elucidating the role of GPER1 and miRNAs in breast cancer might provide new tools for innovative approaches in anti-cancer therapy.

Citing Articles

The GPR30 Receptor Is Involved in IL-6-Induced Metastatic Properties of MCF-7 Luminal Breast Cancer Cells.

Tirado-Garibay A, Ruiz-Barcenas B, Rescala-Ponce de Leon J, Ochoa-Zarzosa A, Lopez-Meza J Int J Mol Sci. 2024; 25(16).

PMID: 39201674 PMC: 11354767. DOI: 10.3390/ijms25168988.


Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.

da Silva F, Brandao D, Ferreira E, Siqueira R, Ferreira H, da Silva Filho A Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895937 PMC: 10610388. DOI: 10.3390/ph16101466.


Different Expression Pattern of G Protein-Coupled Estrogen Receptor GPER1 in Esophageal Squamous Cell Carcinoma and Adenocarcinoma.

Liu J, Niu Y, Zhang B, Sun Q, Li H, Bai L Int J Mol Sci. 2023; 24(18).

PMID: 37762356 PMC: 10531045. DOI: 10.3390/ijms241814055.


Overview of the therapeutic strategies for ER positive breast cancer.

Blakely B, Shin S, Jin K Biochem Pharmacol. 2023; 212:115552.

PMID: 37068524 PMC: 10394654. DOI: 10.1016/j.bcp.2023.115552.


Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer.

Abbas M, Sayed I, Kamel Abdu-Allah A, Kalam A, Al-Sehemi A, Al-Hartomy O Noncoding RNA Res. 2022; 7(4):248-257.

PMID: 36247409 PMC: 9530401. DOI: 10.1016/j.ncrna.2022.09.003.


References
1.
Kim V, Nam J . Genomics of microRNA. Trends Genet. 2006; 22(3):165-73. DOI: 10.1016/j.tig.2006.01.003. View

2.
Elgamal O, Park J, Gusev Y, Azevedo-Pouly A, Jiang J, Roopra A . Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013; 8(10):e76402. PMC: 3788717. DOI: 10.1371/journal.pone.0076402. View

3.
Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

4.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

5.
Jiang Q, He M, Ma M, Wu H, Yu Z, Guan S . MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep. 2015; 35(3):1425-32. DOI: 10.3892/or.2015.4502. View